Prevention

Who Still Benefits from Aspirin for Primary Prevention in 2026?

Quick answer

Aspirin is no longer recommended for broad primary prevention. USPSTF (2022) advises against initiation in ≥60 and supports individualized decisions in 40–59 with 10-year ASCVD ≥10% and low bleed risk. ARRIVE, ASPREE, and ASCEND each showed small ischemic benefit offset by bleeding. For most primary-prevention patients already on aspirin without a clear indication, consider discontinuing — particularly after age 70.

Evidence review

Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.

ASPREE (2018)

PMID 30221595

19,114 healthy adults ≥70

Aspirin 100 mg did not reduce CV events (HR 0.95); increased major bleeding (HR 1.38) and all-cause mortality (HR 1.14).

ASCEND (2018)

PMID 30146931

15,480 adults with diabetes, no CVD

Aspirin 100 mg reduced vascular events 12% (HR 0.88) but increased major bleeding 29% (HR 1.29) — net benefit marginal.

ARRIVE (2018)

PMID 30158069

12,546 moderate-risk primary prevention

No reduction in CV events (HR 0.96) with aspirin; doubled GI bleeding (HR 2.11).

Practical decision algorithm

IfThen
Age ≥60 without ASCVDDo not initiate aspirin. Consider discontinuing if already started without clear indication.
Age 40–59, 10-year ASCVD ≥10%, low bleeding riskShared decision — small net benefit possible. Favor only if ASCVD >20% and no bleed risk factors.
Age <40Aspirin not recommended for primary prevention except in familial hypercholesterolemia with additional risk.
Colorectal cancer prevention in high-risk lynch syndromeAspirin 600 mg/day reasonable (CAPP2 evidence) — individualized decision with GI.
Established ASCVD, CABG, or prior stroke/TIAAspirin still indicated — this is secondary prevention, different calculus.

Guideline position

USPSTF 2022: Grade C for 40–59 with 10-year ASCVD ≥10% and low bleed risk; Grade D for ≥60 (recommend against). ACC/AHA 2019: aspirin may be considered for primary prevention in 40–70 at high ASCVD risk without bleed risk (Class 2b).

Contraindications and cautions

  • Prior GI bleed or peptic ulcer without PPI coverage
  • Bleeding diathesis or platelet disorder
  • Recent hemorrhagic stroke
  • Age ≥70 (per ASPREE) — bleeding risk dominates
  • Severe anemia with unclear cause

Frequently asked questions

Should I stop aspirin in a patient on it for 15 years?
Assess ASCVD event history. If truly primary prevention, shared-decision discontinuation is reasonable — discontinuing long-term aspirin did not increase events in recent observational analyses. Prescribe PPI if continuing with high bleed risk.
Is aspirin still indicated in diabetes primary prevention?
Largely no. ASCEND showed net benefit minimal. ADA 2026: consider only in very-high-risk diabetes (established organ damage, strong family history) with low bleed risk.
What about aspirin during pregnancy?
Different indication — low-dose aspirin (81–162 mg) reduces preeclampsia risk in high-risk pregnancies. ACOG and USPSTF support this use (distinct from general CV primary prevention).
Does coronary calcium change the recommendation?
Possibly. CAC ≥100 raises 10-year ASCVD risk substantially and may tip shared-decision toward aspirin in 40–59. CAC = 0 supports deferring.
How does aspirin interact with SGLT2 inhibitor, PCSK9 inhibitor, or GLP-1?
No pharmacokinetic interactions. Given multiple effective CV-risk-lowering therapies exist, aspirin's marginal benefit in primary prevention is further diluted.

Further reading

Evidence-Based Medicine

Atrial Fibrillation: Rate vs Rhythm Control in 2026 — EAST-AFNET 4 and Beyond

Clinical Reasoning

Acute Coronary Syndrome: STEMI and NSTEMI Management Updates for 2026

Methodology

Shared Decision-Making with Complex Evidence: A Practical Guide

Back to all decision points